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AbsTrACT 
Introduction loss of the cystic fibrosis transmembrane 
conductance regulator in cystic fibrosis (cF) leads to 
hyperabsorption of sodium and fluid from the airway due 
to upregulation of the epithelial sodium channel (enac). 
thickened mucus and depleted airway surface liquid 
(aSl) then lead to impaired mucociliary clearance. enac 
regulation is thus a promising target for cF therapy. Our 
aim was to develop sirna nanocomplexes that mediate 
effective silencing of airway epithelial enac in vitro and 
in vivo with functional correction of epithelial ion and 
fluid transport.
Methods We investigated translocation of 
nanocomplexes through mucus and their transfection 
efficiency in primary cF epithelial cells grown at air–
liquid interface (ali).Short interfering rna (Sirna)-
mediated silencing was examined by quantitative rt-Pcr 
and western analysis of enac. transepithelial potential 
(Vt), short circuit current (isc), aSl depth and ciliary beat 
frequency (cBF) were measured for functional analysis. 
inflammation was analysed by histological analysis of 
normal mouse lung tissue sections.
results nanocomplexes translocated more rapidly than 
sirna alone through mucus. transfections of primary cF 
epithelial cells with nanocomplexes targeting αenac 
sirna, reduced αenac and βenac mrna by 30%. 
transfections reduced Vt, the amiloride-sensitive isc 
and mucus protein concentration while increasing aSl 
depth and cBF to normal levels. a single dose of sirna 
in mouse lung silenced enac by approximately 30%, 
which persisted for at least 7 days. three doses of sirna 
increased silencing to approximately 50%.
Conclusion nanoparticle-mediated delivery of 
enacsirna to ali cultures corrected aspects of the 
mucociliary defect in human cF cells and offers effective 
delivery and silencing in vivo.
InTroduCTIon
Cystic fibrosis (CF) is caused by mutations in the 
CF transmembrane conductance regulator gene 
(CFTR), which encodes a cyclic AMP-activated 
channel for chloride and other anions.1 2 Mutations 
in CFTR also result in upregulation of the epithe-
lial sodium channel (ENaC), leading to imbalanced 
water and ion movement across the airway epithe-
lium.3 4 This results in depletion of the airway 
surface liquid (ASL) and thickened mucus with 
progressive loss of pulmonary function.3 4 There-
fore, ENaC is a promising therapeutic target for CF 
with the potential to restore lung fluid homeostasis 
and thus improve mucociliary clearance. ENaC 
is comprised of α, β and γ subunits. The pore-
forming αENaC subunit is required for full channel 
function. The β and γ subunits are regulators of 
ENaC activity,5 6 and residual ENaC activity can 
be measured in their absence.5 7 The other ENaC 
subunit, δ, is only expressed at low levels in the lung 
of humans and not at all in rodents.8 
Small molecule ENaC inhibitors such as 
amiloride9 and benzamil10 reduce sodium uptake, 
but their effects are short-lived because of drug 
absorption.11 Silencing of ENaC expression, by 
short interfering RNA (siRNA)-mediated RNA 
Key messages
What is the key question?
 ► Can silencing of the airway epithelial sodium 
channel (ENaC) activity correct the mucociliary 
defects associated with the cystic fibrosis (CF) 
epithelium?
What is the bottom line?
 ► Short interfering RNA (SiRNA)-mediated 
silencing of ENaC in vitro in pseudostratified, 
ciliated, air–liquid interface (ALI) models of 
the human airway was shown to correct the 
electrical and mucociliary defects associated 
with the CF epithelium, and in addition, we 
demonstrated efficiency of delivery in vivo to 
murine lung and accumulation of the level of 
silencing by repeated delivery along with safety 
by analysis of inflammation.
Why read on?
 ► We have described a siRNA nanoparticle 
formulation that penetrates mucus to transfect 
CF epithelial cells at ALI, and following 
repeated transfection both at ALI and in vivo 
demonstrated cumulative ENaC silencing to 
achieve the desired functional effect, providing 
evidence to support its further development as 
a novel therapeutic approach.
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interference, offers a more promising therapeutic route.12–14 
Potential advantages of nanoparticle-mediated siRNA therapy 
include its potency, specificity, duration15 and restriction to 
the airways to prevent nephrotoxicity. Transfection of the CF 
airway epithelium requires protection of siRNA from nucleases, 
penetration of the mucus and periciliary liquid layer (PCL) and 
targeted uptake by the epithelial cells16 with purpose-designed 
nanoparticles. Previous attempts to develop ENaC siRNA ther-
apies17 18 were limited by lack of nanoparticles capable to effec-
tively deliver siRNA to the airway epithelium.
Receptor-targeted nanocomplexes (RTNs) comprise multi-
functional mixtures of cationic liposomes (L) and cationic 
targeting peptides (P) that self-assemble, electrostatically on 
mixing with siRNA (R).19–24 Peptide E packages nucleic acids 
through a cationic, oligolysine domain and mediates epithelial 
receptor targeting through a seven-amino acid motif, SERSMNF, 
derived by biopanning of a phage peptide library.25 The targeting 
peptide displays close similarity to receptor binding proteins of 
two intracellular pathogens, rhinovirus and Listeria monocy-
togenes.26 Rhinoviruses bind intercellular adhesion molecule-1 
that is present in the airway epithelium and upregulated in the 
inflamed CF epithelium.27 28 Following receptor-mediated endo-
cytosis, the liposome component destabilises the endosomal 
bilayer allowing nucleic acid release to the cytoplasm before 
endosomal degradation occurs.29 This peptide has been used 
previously for targeted transfection with plasmid DNA,25 mini-
circle DNA30 and siRNA31 of bronchial epithelial cells in vitro 
and in vivo.
In this study, we have investigated the effects of RTN-medi-
ated delivery of αENaC siRNA on pseudostratified, ciliated, 
air–liquid interface (ALI) models of the human CF airway, partic-
ularly the correction of the electrical and mucociliary defects 
associated with the CF epithelium. Finally, we have investigated 
the translational potential of this therapy by delivery of murine 
αENaC siRNA to the lungs of normal mice to assess in vivo 
transfection efficacy in a surrogate model of the human lung, 
including efficacy of repeated delivery as well as safety by anal-
ysis of inflammation.
MATerIAls And MeThods
Full details are available in the online supplementary material.
statistics
Data are expressed as the mean±SEM and analysed using a 
two-tailed, unpaired Student’s t-test or one-way analysis of vari-
ance (ANOVA) and Bonferroni’s post hoc analysis where appli-
cable. We also report other data as median and interquartile 
range (IQR), and these have been analysed using a non-para-
metric Mann-Whitney U test.
resulTs
Assessment of nanocomplex translocation through mucus
Nanocomplexes containing Cy3-labelled siRNA were added 
to the surface of the mucus, then the cumulative concentration 
of fluorophores diffusing through the mucus into the lower 
collection chamber over 60 min was measured and compared 
with siRNA alone and fluorescent cationic, polystyrene (PS) 
nanoparticles. The concentration of RTNs penetrating through 
the CF human airway mucus barrier at 1 hour (figure 1C and 
online supplementary table S1) (441.1±52.7 ng/cm2) was 46% 
of that collected from the normal human airway mucus barrier 
at 1 hour (961.5±44.8 ng/cm2; figure 1B), and this was similar 
for siRNA alone at 43% (390.1±15.8 ng/cm2 through CF human 
airway mucus and 917.3±60.1 ng/cm2 through normal human 
airway mucus). RTN and siRNA penetration through normal 
mucus were similar at 1 hour (figure 1B) (p>0.05, n=6), whereas 
Figure 1 Nanoparticles translocate vertically through the mucus 
barrier. Cy3-siRNA alone, RTNs containing Cy3-siRNA or fluorescent 
polystyrene (PS) nanoparticles were investigated for their translocation 
potential through (A) pig gastric mucus, (B) normal human airway 
mucus and (C) CF human airway mucus. The siRNA that is labelled with 
Cy3 is targeting glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
The experiments were repeated on three occasions, and each point is 
the mean±SEM of triplicate measurements. CF, cystic fibrosis; RTNs, 
receptor-targeted nanocomplexes; siRNA, short interfering RNA.
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in porcine gastric mucus, the RTNs penetrated more rapidly than 
siRNA (figure 1A) (1046.1±47.6 ng/cm2 and 472.0±8.8 ng/cm2 
for RTNs and siRNA alone, respectively; p<0.01, n=6). The 
rate of penetration of pig gastric mucus by cationic PS nanopar-
ticles (55.0±2.1 nm and +23.1±1.1 mV) was not significantly 
different to siRNA alone (figure 1A; 782.7±123.0 ng/cm2 and 
472.0±8.8 ng/cm2 for PS nanoparticles and siRNA alone, respec-
tively at 1 hour), but in CF mucus, PS nanoparticles were signifi-
cantly slower than RTNs or siRNA (figure 1C; 100.0±57.6 ng/
cm2 for PS nanoparticles at 1 hour compared with the concentra-
tions displayed above which were ~4-fold more for both RTNs 
and siRNA alone; p<0.05, n=6).
Diffusion coefficients in the three types of mucus (Dm) and 
water (Dw) were calculated as described in the Methods section. 
Dm/Dw is the relative restriction of diffusion in mucus compared 
with water (table 1). The diffusion of RTNs was 14-fold higher 
than that of siRNA alone in CF mucus (27-fold impedance for 
RTNs compared with 376-fold impedance for siRNA alone) 
despite the nanoparticles being significantly larger (91.9±0.5 nm) 
and more cationic (+35.1±0.6 mV) than siRNA, which is 
approximately 7.5 nm.32 RTNs penetrated normal human mucus 
and pig gastric mucus 8.2-fold and 12.3-fold faster, respectively, 
than siRNA alone (table 1).
In vitro sirnA silencing of enaC in epithelial cells
Peptide-targeted cationic nanocomplexes were then used to 
transfect 16HBE14o- epithelial cells with siRNA targeting 
αENaC. Western blot analysis of αENaC protein showed that 
transfection of 16HBE14o- cells with RTNs at 75 nM siRNA led 
to a decrease in the abundance of both the 90 kDa and the 65 kDa 
αENaC protein bands by 41% and 48%, respectively, compared 
with those transfected with control siRNA (online supplemen-
tary figure S1A,B).
Expression of αENaC in BMI-1 transduced CF bronchial 
epithelial (CFBE) cells33 attained maximal levels after 2–5 
days in ALI cultures (figure 2A), and so, ALI culture transfec-
tions in ongoing experiments were performed after at least 5 
days ALI culture. Transfections of CFBE monolayers with 
100 nM αENaC siRNA reduced αENaC mRNA by 30% (n=3) 
compared with control siRNA-treated cultures (figure 2B). After 
three sequential transfections, performed at 48 hours intervals, 
the level of silencing was improved to 54% (n=3; figure 2B). 
Silencing of αENaC also resulted in a 51% silencing of βENaC 
(n=3; online supplementary table S2) but not the γ subunit 
(figure 2C). The α subunit in CFBE cells was 74.9-fold and 19.7-
fold overexpressed relative to the γ and β subunits, respectively 
(online supplementary figure S2, n=3).
Functional effects of enaC silencing
We next investigated the effects of αENaC silencing on 
amiloride-sensitive ENaC-mediated short circuit current (Isc) in 
CFBE cells cultured at ALI 2 days after transfection (figure 3A). 
The amiloride-sensitive Isc was reduced in cells treated with 
αENaC siRNA (median: 6.4 µA/cm2; IQR: 5.4–9.8 µA/cm2; 
n=6) compared with control siRNA (median: 11.5 µA/cm2; 
IQR: 10.1–14.1 µA/cm2; p<0.05, n=8) or untreated cells 
(median: 14.3 µA/cm2; IQR: 13.2–17.9 µA/cm2; p<0.01, n=5) 
(figure 3B,C; online supplementary table S3). As expected, 
CFBE cells showed a very limited response to forskolin (a 
cAMP agonist) or GlyH-101 (a CFTR inhibitor) under any 
of the conditions examined (figure 3B) as opposed to normal 
human bronchial epithelial (NHBE) cells (online supplemen-
tary figure S3). Transepithelial electrical resistance (Rt) was not 
perturbed by the transfection procedure (online supplementary 
figure S4), with ENaC-silenced cells having a median of 693.5 
(IQR: 565.7–805.8) Ω cm2 (n=7) compared with 783.2 (IQR: 
711.1–953.2) Ω cm2 and 676.7 (IQR: 653.1–744.2) Ω cm2 for 
control siRNA (n=7) and untreated cells (n=3), respectively 
(online supplementary table S3).
We then performed three sequential siRNA transfections of 
CFBE cells at 48-hour intervals and determined physiological 
responses to ENaC silencing. Mucus was not removed during 
this period (unwashed cells). Samples treated with αENaC 
siRNA had lower negative transepithelial potentials (Vt) (median: 
−7.2 mV; IQR: −5.7 mV to −12.2 mV) than those transfected 
with control siRNA (median: −16.0 mV; IQR: −14.8 mV to 
−19.0 mV) (figure 3D; n=5) as measured by scanning ion-con-
ductance microscopy. The median Vt value for the VX-770 
and VX-809-treated CF cells was −6.8 mV (IQR: −6.7 mV to 
−12.7 mV), while for untreated, non-CF cells, it was −7.7 mV 
(IQR: −6.3 mV to −11.6 mV; online supplementary table S4).
The ASL depth in CFBE ALI cultures was increased by ~1.5 fold 
(median: 12.1 µm; IQR: 10.7–14.9 µm) after silencing of 
αENaC compared with control siRNA-treated (median: 7.9 µm; 
IQR: 6.4–9.8 µm) and untreated cells (median: 8.2 µm; IQR: 
5.8–11.1 µm) (p<0.001, n=4) (figure 4A,B; online supplemen-
tary table S4). The ciliary beat frequency (CBF) of unwashed 
CFBE cells increased to 14.5±0.5 Hz from 9.6±0.7 Hz in 
untreated CFBE cultures following sequential treatment with 
αENaC siRNA (p<0.001, n=10), compared with 11.9±1.0 Hz 
in control siRNA-treated cells (p<0.05, n=10) (figure 4C). The 
CBF of VX-770 and VX-809-treated cells was also increased to 
12.8±0.5 Hz (p<0.05, n=10; online supplementary table S4).
Cells treated with αENaC siRNA displayed reduced net fluid 
absorption rates from the apical side of the epithelium with a 
median value of 0.9 µL/cm2/hour (IQR: 0.6–1.3 µL/cm2/hour), 
which was lower than that of both control siRNA-treated 
cells (median: 1.6; IQR: 1.3–1.9 µL/cm2/hour; p<0.05, n=4) 
and untreated cells at 1.5 µL/cm2/hour (IQR: 1.1–1.9 µL/cm2/
hour; figure 4D; online supplementary table S4). Finally, we 
measured the total protein concentration in mucus collected 
from each well of the sequentially transfected CF monolayers. 
Table 1 A comparison of the nanoparticle effective diffusion rate in mucus (Dm) and the effective diffusion rate in water (Dw) of the receptor-
targeted nanocomplexes (RTNs), polystyrene (PS) nanoparticles and siRNA alone through three different types of static layers of mucus. Dm/Dw is the 
relative restriction of diffusion in mucus compared with water.
Particle
diffusion in PGM 
(cm2 s−1) dm/dw (PGM)
diffusion in nM
(cm2 s−1) dm/dw (nM)
diffusion in CFM 
(cm2 s−1) dm/dw (CFM)
siRNA 3.75×10−9 1.57×10−2 1.31×10−8 1.11×10−2 2.33×10−9 2.66×10−3
RTNs 1.38×10−8 1.93×10−1 8.71×10−9 9.12×10−2 2.67×10−9 3.74×10−2
PS 5.75×10−9 4.82×102   −   −   N/A   N/A
CFM, cystic fibrosis human airway mucus; N/A, data not applicable as effective translocation was not achieved; NM, normal human airway mucus; PGM, pig gastric mucus; PS, 
polystyrene; RTN, receptor-targeted nanocomplex; siRNA, short interfering RNA.
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The apical surface of each well was washed with PBS 2 days 
after the first (figure 5A) and second transfections (figure 5B) 
and 7 days after the third (figure 5C) transfection. In all cases, 
the protein concentration in mucus from the αENaC-silenced 
cells (n=6) was significantly lower than that from the control 
siRNA-treated cells (n=6), VX-770 and VX-809-treated cells 
(n=4) or untreated cells (n=3), and this effect lasted for at least 
7 days post-transfection. At the end of the experiment, at 8 days 
post-transfection with αENaC siRNA (n=6), αENaC expression 
was still 27% lower than control siRNA-treated cells (p<0.05; 
figure 5D).
In vivo lung delivery
We then investigated delivery of siRNA into the lungs of 
normal mice to assess the translational potential of αENaC 
siRNA delivery. The biodistribution analysis of nanocomplexes 
containing Dy677-labelled siRNA 24 hours after oropha-
ryngeal instillation showed very high retention of siRNA in 
lungs (figure 6A) with low-level fluorescence in intestines 
(online supplementary figure S5, p<0.05, n=3) which probably 
reflects incidental swallowing during administration. There was 
no fluorescence in heart, liver, kidneys and spleen suggesting no 
detectable transfer of the siRNA from the lung to the circulation 
(figure 6A). Transfecting mice by oropharyngeal instillation with 
αENaC siRNA (n=7) or control siRNA (n=7) silenced αENaC 
by 30% at the mRNA level compared with control siRNA 
(p<0.01) (figure 6B). Silencing of αENaC 1 week after transfec-
tion remained at 23% compared with control siRNA (figure 6C; 
n=4 for untreated, n=6 for control siRNA and n=7 for αENaC 
siRNA-treated mice) and was not significantly different from 
silencing at 48 hours. Repeated transfections with αENaC 
siRNA (n=8) demonstrated cumulative silencing, increasing to 
58% reduction compared with control siRNA at 72 hours after 
the third instillation of αENaC siRNA (figure 6D; online supple-
mentary table S5).
The RTN siRNA formulations were well tolerated by the mice 
for single or triple dosing (online supplementary figure S6A,B). 
H&E staining of lung sections (n=3) showed that treatment 
with RTNs containing ENaC siRNA induced sporadic mild 
peribronchial cell infiltrates, the size and severity of which was 
unaffected by the number of instillations (figure 7A,B). Control 
siRNA induced a similar inflammatory response, although the 
foci were generally smaller and less frequent than with ENaC 
siRNA (figure 7C).
dIsCussIon
The lack of functional CFTR and hyperactivity of ENaC in 
the airways of patients with CF leads to disrupted ion and 
fluid homeostasis.3 Modulators of CFTR such as ivacaftor and 
the ivacaftor/lumacaftor (Orkambi) combination therapy offer 
treatment for patients with specific mutations,34 35 but there 
are some mutation classes where CFTR modulators will not be 
effective, such as nonsense mutations, and so other therapeutic 
strategies are required. The low-volume hypothesis of CF lung 
disease links increased activity of ENaC with ASL depletion in 
CF3 and so reducing transepithelial sodium absorption through 
ENaC is an alternative target for therapeutics.11 36 The role of 
ENaC in regulating ASL volume has been validated in recent 
work showing that inhibition of ENaC proteolytic activation 
using the SPLUNC1 or peptide fragments37–39 or QUB-TL140 
successfully prevented dehydration of the ASL in CF HBEC 
monolayers. Small molecule inhibitors of ENaC suffer from 
rapid systemic absorption from the lung and are associated 
Figure 2 ENaC expression over time of primary cells growing at ALI 
and silencing of ENaC. (A) The fold-difference in endogenous αENaC 
gene expression relative to β-actin was quantified by qRT-PCR in 
CFBE cells from the start date of ALI cultures (mean of n=3 per time 
point). Points represent mean values±SEM. (B) RTN formulations 
containing either αENaC siRNA or control siRNA at 100 nM were used 
in transfections of CFBE cells grown at ALI for 6 weeks. Transfections 
were performed once (single) or sequentially every other day (triple), 
and the percentage of silencing was calculated 48 hours after the last 
transfection (n=3 per formulation). The middle horizontal lines represent 
the median values. Silencing is normalised to the mean control siRNA 
set at 100%. (C) CFBE cells grown at ALI were triple-transfected with 
RTN formulations containing either αENaC siRNA or control siRNA at 
100 nM, and the percentage of silencing of α, β and γ ENaC subunits 
was then calculated 48 hours after transfection (n=3 per formulation). 
The middle horizontal lines represent the median values. Silencing is 
normalised to the mean control siRNA set at 100%. Non-parametric 
Mann-Whitney U tests were performed, and no statistical significant 
differences were achieved. ALI, air–liquid interface; CFBE, cystic fibrosis 
bronchial epithelial cells; ENaC, epithelial sodium channel; RTN, 
receptor-targeted nanocomplex; siRNA, short interfering RNA.
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with side effects such as hyperkalaemia due to ENaC inhibi-
tion in the kidney or pulmonary oedema.11 41 42 We have there-
fore investigated ENaC silencing mediated by nanoparticles 
carrying siRNA.
We used siRNA to target the major subunit, αENaC. The 
αENaC subunit forms a sodium-conducting pore, while the 
other two subunits enhance its activity.43 The α subunit is crit-
ical for sodium transport function and volume regulation as 
demonstrated in αENaC knockout mice, which die soon after 
birth due to a failure to clear their lungs of fluid.44 In addition, 
it has been shown that a low mRNA abundance of αENaC in the 
nasal epithelium of premature infants is linked with respiratory 
Figure 3 Single transfection of CFBE air–liquid interface (ALI) cell monolayers with nanocomplexes containing αENaC siRNA reduces the amiloride-
sensitive short circuit current (Isc). (A) A schematic highlighting experiments performed after single or triple transfections on CFBE cells grown at ALI. 
(B) Representative Isc traces from CFBE monolayers in Ussing chambers of cells treated with 100 nM αENaC siRNA or control siRNA or untreated 
cells. (C) The change in Isc (ΔIsc) after application of 10 µM amiloride is shown for the αENaC siRNA-treated cells (Ussing chambers; n=6), the control 
siRNA-treated cells (n=8) and the untreated CFBE cells (n=5). Median values are presented as bars and IQR by upper and lower horizontal lines, with 
statistical significance determined by the non-parametric Mann-Whitney U test. Asterisks indicate comparisons of specific formulations with statistical 
significance (*p<0.05; **p<0.01). (D) Transepithelial potential (Vt) of αENaC siRNA-treated monolayers of CFBE cells cultured for 4 weeks on ALI. 
Wells were triple-transfected with 100 nM αENaC siRNA (n=5) or control siRNA (n=5) and then Vt measurements performed 3 days after the last 
transfection using scanning ion-conductance microscopy (SICM). Further samples were treated with 10 µM VX-809 1 day prior to Vt measurement and 
treated with 10 µM VX-770 during measurement (for approximately 20 min; n=4). Median values are presented as bars and IQR by upper and lower 
horizontal lines. Non-parametric Mann-Whitney U tests were performed, and no statistical significant differences were achieved. ASL, airway surface 
liquid; CBF, ciliary beat frequency; CFBE, cystic fibrosis bronchial epithelial cells; ENaC, epithelial sodium channel; siRNA, short interfering RNA.
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failure.45 Lastly, a mutation that leads to αENaC hyperactivity 
was found in patients with atypical CF.46
Nanoparticles offer protection to the siRNA during nebulisa-
tion and from nuclease attack in lung fluids and enable penetra-
tion of extracellular barriers such as mucus and the PCL47 before 
entering the epithelial cells by endocytosis. RTNs, comprising 
the oligolysine epithelial-targeting peptide (peptide E) and the 
liposome DOTMA/DOPE, self-assemble on mixing lipid and 
peptide components with siRNA to form cationic, monodisperse 
nanoparticles with a size of approximately 90 nm, which have 
been used previously for lung delivery of nucleic acids (including 
by nebulisation) in mice and pigs.25 26 30 31 48 Similar RTN formu-
lations can package and transfect siRNA efficiently,20 23 24 49 and 
so we are now investigating use of αENaC siRNA to assess its 
therapeutic potential in epithelial lung models in vitro and in 
vivo.
We first assessed the ability of RTNs to penetrate mucus, 
which presents a physical barrier to nanoparticle siRNA delivery 
in the airways. Mucus is a gel-like layer, rich in charged mucin 
glycoproteins covering the lung epithelium and is particularly 
thick and sticky in the CF lung.50 51 Differentiated ALI cultures 
of human airway epithelial cells produce copious amounts of 
Figure 4 Effect of triple transfections of CFBE ALI cells with nanocomplexes containing αENaC siRNA. The CFBE cells were cultured in snapwells for 
4 weeks then treated with 100 nM αENaC siRNA or control siRNA at 48 hours intervals and the measurements performed 3 days after the third dose. 
(A) ASL depth measurements of CFBE monolayers as determined by confocal microscopy. XZ representative images of fluorescently labelled ASL (red) 
and cells (green). Top: untreated cells, middle: cells transfected three times with 100 nM of control siRNA and bottom: cells transfected three times 
with 100 nM of αENaC siRNA. A white bar has been included to denote the ASL measurement. (B) ASL depth measurement of each treatment group 
(n=4). Bars represent mean±SEM, while asterisks indicate statistical significance of comparisons between the αENaC siRNA-treated cells versus the 
controls (***p<0.001) determined by an ANOVA test followed by Bonferroni's post hoc test. (C) Effect of αENaC siRNA, control siRNA and VX-770 
and VX-809 on ciliary beat frequency (CBF) of CFBE cells grown at ALI. For each experimental condition (n=10), readings of CBF were calculated 
from 10 ciliated areas in the snapwell, and the data represent the mean±SEM. Asterisks indicate comparisons of specific formulations with statistical 
significance (*p<0.05; **p<0.01; ***p<0.001) determined by an ANOVA test followed by Bonferroni's post hoc test. (D) Transepithelial fluid 
transport through human CFBE cells. Net fluid absorption rate was measured 4 days after cell treatment with a control siRNA or with αENaC siRNA. 
Bars represent the median value with IQR shown by the horizontal lines (n=4), while asterisks indicate statistical significance (*p<0.05) determined 
by non-parametric Mann-Whitney U tests. ALI, air–liquid interface; ASL, airway surface liquid; CFBE, cystic fibrosis bronchial epithelial cells; ENaC, 
epithelial sodium channel; siRNA, short interfering RNA.
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mucus, which is particularly viscous from CF cells.52 RTN diffu-
sion in mucus from three sources was used including porcine 
gastric mucus and human mucus from differentiated CF and 
non-CF airway epithelial cultures. RTN diffusion rates were 
lowest in CF mucus, consistent with its increased viscosity. RTNs 
diffused at similar rates to siRNA alone in CF and non-CF mucus 
despite their size and charge differences. The diffusion rates of 
RTNs were greater than those of cationic PS nanoparticles of 
similar size used in cervicovaginal mucus,53 54 suggesting that 
surface properties of RTNs contribute to their mucus mobility.32
Silencing levels of αENaC by 30% from a single dose 
were achieved, which resulted in a significant reduction in 
amiloride-sensitive Isc compared with control siRNA and untrans-
fected cells. Silencing did not affect Rt indicating that there was 
no damage to the epithelial tight junctions by the nanoparticle 
complex directly or by decreased cell viability and that the 
changes in Isc were a direct effect of reduced αENaC activity. 
Interestingly βENaC, but not γENaC, was also silenced by 
αENaC siRNA. This was observed in other studies,17 suggesting 
transcriptional feedback inhibition of βENaC by αENaC.
Enhancement of silencing of αENAC to 50% by three sequen-
tial transfections in CFBE cells reduced the transepithelial poten-
tial to normal range values (−7 mV) in ALI cultures.55 This may 
be a useful therapeutic biomarker as CF individuals display 
hyperpolarised nasal transepithelial potentials.56 Silencing of 
αENAC also caused a significant reduction in fluid absorption 
and increased ASL depth to normal levels. Increased hydration 
of the epithelial surface was also indicated by the reduced total 
protein concentration in mucus washings from αENaC siRNA-
treated cultures for at least a week post-transfection, whereas 
Figure 5 Protein concentration in mucus collected at different time points from transfected or untreated CFBE cells grown at ALI and in 
vitro silencing after three transfections. Mucus collections were done (A) 2 days after the first transfection (αENaC siRNA treated, n=6; control 
siRNA treated, n=3; untreated controls, n=3), (B) 2 days after the second transfection (αENaC siRNA treated, n=6; control siRNA treated, n=3; VX-770 
and VX-809 treated, n=3; untreated controls, n=3) and (C) 7 days after the third transfection (αENaC siRNA treated, n=6; control siRNA treated, n=3; 
VX-770 and VX-809 treated, n=3; untreated controls, n=3). The concentration levels were normalised to those of the untreated cells. (D) Formulations 
containing either 100 nM αENaC siRNA (n=6) or control siRNA (n=3) were used in three sequential transfections of CFBE-BMI-1 cells grown at ALI for 
4 weeks, and the percentage of silencing was calculated 8 days after the third transfection. Silencing was normalised to the mean control siRNA set 
at 100%. The middle horizontal lines represent the median values. Asterisks indicate comparisons of specific formulations with statistical significance 
(*p<0.05) determined by non-parametric Mann-Whitney U tests. ALI, air–liquid interface; CFBE, cystic fibrosis bronchial epithelial cells; ENaC, 
epithelial sodium channel; siRNA, short interfering RNA.
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the CFTR potentiator/corrector drug combination, VX-770 and 
VX-809, showed no effect on mucus protein concentration.
We further hypothesised that increased ASL depth would 
reduce impedance of ciliary motility. Indeed, we found that the 
CBF in ENaC siRNA-treated CF cells was increased to ~15 Hz, 
which compares well with normal CBF of approximately 16 Hz.57 
Furthermore, the siRNA induced changes in CBF and fluid height 
after three doses, which was consistent with that reported for 
current drugs used to correct CFTR activity. VX-770 on its own 
increased CBF,58 whereas the VX-770 and VX-809 combination 
increased ASL height59 (both studies following five consecutive 
day treatments).
This study suggests that silencing ENaC in the range of 
30%–50% is sufficient for restoration of epithelial ion transport 
balance, fluid transport and mucociliary properties. In previous 
αENaC silencing studies with siRNA, transfections were 
performed pre-ALI as transfections at ALI were ineffective,18 
although they reported correction of the short circuit current 
and increased ASL when using siRNAs targeting both α and 
βENaC.18 Another study showed that silencing of αENaC with 
a commercial transfection reagent in submerged cultures lasted 
for at least 3 days, although they did not perform transfections at 
ALI.13 They also reported 35%–40% silencing in vivo with a lipo-
somal formulation from a single administration that persisted at 
least 72 hours.13 Finally, an shRNA approach following lentiviral 
transduction of immortalised and primary cell lines used αENaC 
as their target.12 The authors transduced primary cells before the 
formation of tight junctions, unlike our fully differentiated cell 
Figure 6 In vivo lung administration of siRNA-containing nanocomplexes. (A) Uptake of Dy677-siRNA formulations following oropharyngeal 
administration. Twenty-four hours later, the mice were culled (n=3 per group), and organs (heart, lung, liver, kidneys, spleen and intestines) were 
extracted and imaged for fluorescence. (B–D) The remaining αENaC mRNA was quantified by qRT-PCR in C57BL6 female mice after instillation of 
cationic nanocomplexes containing 16 µg αENaC siRNA (n=7) or control siRNA (n=6) at (B) 48 hours and (C) 7 days. (D) The amount of remaining 
αENaC mRNA detected by qRT-PCR in C57BL6 female mice at 72 hours after the last of three instillations of cationic nanocomplexes containing 16 µg 
αENaC siRNA (n=8) or control siRNA (n=7). Silencing was normalised to the mean control siRNA set at 100%. Medians and IQRs are presented by 
horizontal lines. Asterisks indicate comparisons of specific formulations with statistical significance (*p<0.05; **p<0.01; ***p<0.001) determined by 
non-parametric Mann-Whitney U tests. ENaC, epithelial sodium channel; siRNA, short interfering RNA.
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approach, and showed up to 60% silencing. Similar to our find-
ings, they have shown that reducing mRNA results in propor-
tional changes in the short circuit current responses and also 
reduced net apical to basal fluid flux. In addition, they demon-
strated that, at a high lentiviral dose, the βENaC mRNA was 
reduced, but γENaC was not, which is in agreement with our 
findings.
We finally quantified ENaC silencing, after single or repeat 
siRNA dosing (by oropharyngeal instillation) in the lungs of 
normal mice. The tolerance of repeated dosing supports the 
hypothesis that our nanoparticles do not induce neutralising 
antibodies, which is important for a potential life-long therapy. 
Minimal effective modulation of ENaC activity by repeated 
dosing of siRNA is likely to be much safer than complete inacti-
vation of αENaC, since this could result in negative effects such 
as oedema observed in lungs of ENaC knockout mice.44 There 
were no significant adverse effects of repeated dosing of RTNs 
in mice as judged by body weight and behaviour. There was 
only minimal focal inflammation assessed histologically and the 
nanocomplex biodistribution was restricted to the lungs. Trans-
fection experiments at ALI with human CFBE cells suggested 
that silencing of αENaC in the range of 30%–50% was suffi-
cient for restoration of epithelial ion transport balance, fluid 
transport and mucociliary properties. We have shown that RTNs 
achieve these levels of silencing in mice and that the silencing is 
persistent for at least 1 week. These findings support the trans-
lational potential of this nanoparticle-mediated siRNA therapy 
for CF.
In summary, we have described nanoparticles that can pene-
trate mucus effectively and deliver siRNA to the airway epithe-
lium and that silencing of αENaC can be achieved in vitro and 
in vivo leading to improved hydration and mucociliary function 
in CFBE monolayers. Other studies have also shown functional 
correction of airway epithelial cells but only by transfection 
prior to ALI culture. RTNs represent a powerful new tool for 
siRNA transfection studies in differentiated respiratory epithelial 
cells and in vivo. The potential to regulate ENaC to a minimally 
effective level, the persistence of silencing for at least 1 week and 
restriction of distribution to the lung after airway administration 
indicates translational potential and suggests advantages in effi-
cacy and safety over orally administered, small molecule drugs.
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